Skip to main content
Home > Week in Review > Clinical Status

Chronological Index of : Clinical Status

 Current Issue
  • Anti-IL-6R: Phase IIb started

    Ablynx N.V. (Euronext:ABLX), Ghent, Belgium AbbVie Inc. (NYSE:ABBV), Chicago, Ill. Product: Anti-IL-6R (ALX-0061) Business: Autoimmune Molecular target: Interleukin-6 (IL-6) receptor (CD126) Description: Nanobody …

    Published on 3/30/2015
  • AZP-531: Phase IIa started

    Alize Pharma, Lyon, France Product: AZP-531 Business: Endocrine/Metabolic Molecular target: Ghrelin Description: Unacylated ghrelin analog Indication: Treat Prader-Willi syndrome Endpoint: Safety; effects on fullness/…

    Published on 3/30/2015
  • CLS-TA: Phase II started

    Clearside Biomedical Inc., Alpharetta, Ga. Product: CLS-TA, CLS-1001 Business: Ophthalmic Molecular target: Glucocorticoid receptor (GCCR) Description: Triamcinolone acetonide delivered using the companys ocular …

    Published on 3/30/2015
  • DPX-Survivac: Phase II started

    Immunovaccine Inc. (TSX:IMV), Halifax, Nova Scotia Product: DPX-Survivac Business: Cancer Molecular target: Survivin (BIRC5) Description: Vaccine comprising survivin (BIRC5)-based peptide antigens formulated using …

    Published on 3/30/2015
  • Epi proColon: Clinical trial completed enrollment

    BioChain Institute Inc., Newark, Calif. Epigenomics AG (Xetra:ECX; OTCQX:EPGNY), Berlin, Germany Product: Epi proColon, Epi proColon 2.0 Business: Diagnostic Molecular target: Septin 9 (SEPT9) Description: Second-…

    Published on 3/30/2015
  • Fruquintinib: Completed Phase II enrollment

    Hutchison China MediTech Ltd. (LSE:HCM), Hong Kong, China Eli Lilly and Co. (NYSE:LLY), Indianapolis, Ind. Product: Fruquintinib (HMPL-013) Business: Cancer Molecular target: Vascular endothelial growth factor (VEGF) …

    Published on 3/30/2015
  • GCS-100: Phase IIb started

    La Jolla Pharmaceutical Co. (NASDAQ:LJPC), San Diego, Calif. Product: GCS-100 Business: Renal Molecular target: Galectin-3 (LGALS3) Description: Galectin-3 (LGALS3) inhibitor Indication: Treat stage 3b or 4 chronic …

    Published on 3/30/2015
  • Geodon ziprasidone: Phase III started

    RaQualia Pharma Inc. (JASDAQ:4579), Nagoya, Japan Meiji Seika Pharma Co. Ltd., Tokyo, Japan Pfizer Inc. (NYSE:PFE), New York, N.Y. Product: Geodon ziprasidone (ME2112) Business: Neurology Molecular target: Serotonin (5-…

    Published on 3/30/2015
  • LJPC-501: Phase III started

    La Jolla Pharmaceutical Co. (NASDAQ:LJPC), San Diego, Calif. Product: LJPC-501 Business: Cardiovascular Molecular target: NA Description: Renin-angiotensin system peptide agonist Indication: Treat catecholamine-…

    Published on 3/30/2015
  • Onfi clobazam: Phase III started

    H. Lundbeck A/S (CSE:LUN), Copenhagen, Denmark Product: Onfi clobazam Business: Neurology Molecular target: GABA A receptor Description: 1,5-benzodiazepine Indication: Adjunctive treatment of Dravet syndrome Endpoint: …

    Published on 3/30/2015
  • Retosiban: Phase III started

    GlaxoSmithKline plc (LSE:GSK; NYSE:GSK), London, U.K. Product: Retosiban (GSK221149) Business: Genitourinary Molecular target: Oxytocin receptor (OXTR) Description: Small molecule oxytocin receptor (OXTR) antagonist …

    Published on 3/30/2015
  • Rhopressa: Completed Phase III enrollment

    Aerie Pharmaceuticals Inc. (NASDAQ:AERI), Bedminster, N.J. Product: Rhopressa (AR-13324) Business: Ophthalmic Molecular target: Rho kinase; Norepinephrine transporter Description: Dual inhibitor of Rho kinase and the …

    Published on 3/30/2015
  • Scyllo-inositol: Completed Phase II enrollment

    Transition Therapeutics Inc. (TSX:TTH; NASDAQ:TTHI), Toronto, Ontario Product: Scyllo-inositol (AZD-103, ELND005) Business: Neurology Molecular target: Beta amyloid Description: Small molecule that disaggregates beta …

    Published on 3/30/2015
  • Sotagliflozin: Phase III started

    Lexicon Pharmaceuticals Inc. (NASDAQ:LXRX), The Woodlands, Texas Product: Sotagliflozin (LX4211 tablet) Business: Endocrine/Metabolic Molecular target: Sodium-glucose cotransporter 1 (SGLT1); Sodium-glucose …

    Published on 3/30/2015
  • TTFields: Phase II started

    Novocure Ltd., Isle of Jersey Product: TTFields Business: Cancer Molecular target: NA Description: Low intensity, intermediate frequency, alternating electric fields that disrupt mitosis and cytokinesis delivered via …

    Published on 3/30/2015
  • ZL-2102: Phase I started

    Zai Laboratory Inc., Shanghai, China Sanofi (Euronext:SAN; NYSE:SNY), Paris, France Product: ZL-2102 Business: Pulmonary Molecular target: NA Description: Anti-inflammatory compound Indication: Treat chronic respiratory…

    Published on 3/30/2015
  • Zorblisa: Phase III started

    Scioderm LLC, Raleigh, N.C. Product: Zorblisa (SD-101) Business: Dermatology Molecular target: NA Description: Undisclosed topical cream Indication: Treat epidermolysis bullosa Endpoint: Proportion of patients achieving…

    Published on 3/30/2015
  • ATB-346: Development resumed

    Antibe Therapeutics Inc. (TSX-V:ATE; OTCQX:ATBPF), Hamilton, Ontario Product: ATB-346 Business: Autoimmune Molecular target: Cyclooxygenase-1 (COX-1); Cyclooxygenase-2 (COX-2) Description: Hydrogen sulfide-releasing …

    Published on 3/23/2015
  • Favipiravir: Completed Phase III enrollment

    MediVector Inc., Boston, Mass. Toyama Chemical Co. Ltd., Tokyo, Japan Product: Favipiravir (Avigan) (T-705) Business: Infectious Molecular target: Viral polymerase Description: Viral RNA polymerase inhibitor Indication:…

    Published on 3/23/2015
  • MGD010: Phase I started

    MacroGenics Inc. (NASDAQ:MGNX), Rockville, Md. Product: MGD010 Business: Autoimmune Molecular target: Fc gamma receptor IIb (FCGR2B) (CD32B); CD79b molecule immunoglobulin-associated beta (CD79B) (B29) Description: …

    Published on 3/23/2015
  • MM-121: Phase II started

    Merrimack Pharmaceuticals Inc. (NASDAQ:MACK), Cambridge, Mass. Product: MM-121, SAR256212 Business: Cancer Molecular target: Epidermal growth factor receptor 3 (EGFR3) (HER3) (ErbB3) Description: Human mAb against …

    Published on 3/23/2015
  • MOR209/ES414: Phase I started

    Emergent BioSolutions Inc. (NYSE:EBS), Rockville, Md. MorphoSys AG (Xetra:MOR; Pink:MPSYF), Martinsried, Germany Product: MOR209/ES414 (formerly ES414) Business: Cancer Molecular target: Prostate-specific membrane …

    Published on 3/23/2015
  • NI-0501: Phase II amended

    Novimmune S.A., Plan-les-Ouates, Switzerland Product: NI-0501 Business: Hematology Molecular target: Interferon (IFN) gamma Description: Human mAb against interferon (IFN) gamma Indication: Treat hemophagocytic …

    Published on 3/23/2015
  • Oral ifetroban: Phase II started

    Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX), Nashville, Tenn. Product: Oral ifetroban (Boxaban) Business: Pulmonary Molecular target: Thromboxane A2/prostaglandin H2 (TXA2/PGH2) receptor Description: Oral thromboxane …

    Published on 3/23/2015
  • Oral omecamtiv mecarbil: Completed Phase II enrollment

    Amgen Inc. (NASDAQ:AMGN), Thousand Oaks, Calif. Cytokinetics Inc. (NASDAQ:CYTK), South San Francisco, Calif. Product: Oral omecamtiv mecarbil Business: Cardiovascular Molecular target: Cardiac myosin Description: …

    Published on 3/23/2015

< Previous   1  2  3  4  5  Next >
Subscribe Now
Free Trial

About BioCentury

Decision-shaping business intelligence for the global biotech and pharma industry since 1993